TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30107283
Drug: MEDI3902 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3902 (750 mg)
Study: 30107283
Drug: MEDI3902 (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3902 (1500 mg)
Study: 30107283
Drug: MEDI3902 (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3902 (3000 mg)
Study: 29943364
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment (100 mg/day)
Study: 1936422
Drug: Omnipaque 350
Normalized name: Omnipaque 350
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omnipaque 350 (75.49% iohexol, 350 mgI ml‐1)
Study: 1936422
Drug: Angioconray (80%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angioconray (80% sodium iothalamate, 480 mgI ml‐1)
Study: 28585735
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg green tea extract, two capsules/day
Study: 28585735
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg starch, two capsules/day
Study: 24993562
Drug: SINGLE (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: SINGLE (once daily training)
Study: 24993562
Drug: REPEATED (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: REPEATED (twice every second day training)
Study: 21372694
Drug: Amlodipine/valsartan (5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (5/160 mg) in the morning
Study: 21372694
Drug: Amlodipine/valsartan (5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (5/160 mg) in the evening
Study: 21372694
Drug: Amlodipine/valsartan (10/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (10/160 mg) after uptitration if needed
Study: 15380292
Drug: Cocaine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (150 mg)
Study: 9701103
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine (10-40 mg/d), possibly combined with enalapril maleate (5-20 mg/d) and/or hydrochlorothiazide (12.5-25 mg/d)
Study: 8149523
Drug: Clinical and
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical and biochemical variables (age, previous treatment for systemic hypertension, presence of clinical heart failure, plasma atrial natriuretic factor levels)
Study: 16351387
Drug: Daily Abstinence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Abstinence Self-Efficacy (ASE)
Study: 2190851
Drug: Pentasa (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa (1.5 g daily)
Study: 2190851
Drug: Placebo (dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dummy tablet)
Study: 7438324
Drug: Cystectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystectomy plus preoperative irradiation (6.5 Gy X 2F/1 week) with misonidazole (3 g/m2, two doses, orally)
Study: 7438324
Drug: Cystectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystectomy plus preoperative irradiation (4.0 Gy X 5F) with misonidazole (2 g/m2)
Study: 7438324
Drug: Split course
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split course (SC) protracted regime with misonidazole (0.5 g/m2 daily doses, total dose 14 g/m2 over 61 days)
Study: 7438324
Drug: Hyperfractionation (HF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionation (HF) with misonidazole (2 g/m2 daily doses, total dose 14 g/m2 over 35 days)
Study: 31251892
Drug: RPE-guided aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RPE-guided aerobic training (n=11; 16 weeks, 20 min, twice weekly at RPE 3-6)
Study: 27577177
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (POMx), 2 capsules of 250 mg per day for 8 weeks
Study: 27577177
Drug: Cellulose (control),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose (control), 2 capsules of 250 mg per day for 8 weeks
Study: 26176930
Drug: sham tDCS/escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham tDCS/escitalopram 20 mg/day
Study: 26176930
Drug: sham tDCS/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham tDCS/placebo pill
Study: 22717170
Drug: l‐tryptophan (2.8g/d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐tryptophan (2.8g/d)
Study: 22358274
Drug: TENS (Transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS (Transcutaneous Electrical Nerve Stimulation) applied for 30 minutes, three times a day, along with analgesic therapy and physiotherapy.
Study: 22358274
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received more physiotherapy analgesic therapy without TENS.
Study: 18327706
Drug: Aprepitant-based regimen
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant-based regimen (day 1: aprepitant 125 mg, ondansetron 8 mg, dexamethasone 12 mg before chemotherapy; ondansetron 8 mg 8 h later; days 2-3: aprepitant 80 mg qd)
Study: 18327706
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (day 1: ondansetron 8 mg and dexamethasone 20 mg before chemotherapy; ondansetron 8 mg 8 h later; days 2-3: ondansetron 8 mg bid)
Study: 15033400
Drug: Yasmin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yasmin (30 microg ethinylestradiol + 3 mg drospirenone)
Study: 11793859
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CSA) at an initial dosage of 5 mg.kg‐1.d‐1, gradually tailed off over three months and maintained at 2 mg.kg‐1.d‐1 for 12 months.
Study: 11793859
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) at a dosage of 37.5 mg/day.
Study: 8063043
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of the ACTH4-9 analogue ORG 2766 every 24 h
Study: 3281838
Drug: Sodium meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium meglumine ioxaglate (320 or 306 mg I/ml)
Study: 3281838
Drug: Meglumine diatrizoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine diatrizoate (306 mg I/ml)
Study: 28760121
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TA) 10 mg/kg 20 minutes preoperatively and 3 hours after first dose
Study: 28760121
Drug: Intra-articular tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular tranexamic acid (TA) 3 g locally into surgical site
Study: 18363581
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (150 mg, 3 times daily for 1 week after each blood donation)
Study: 16492219
Drug: Glibenclamide (5.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5.25 mg)
Study: 12671696
Drug: Active lozenges
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active lozenges (PTA) containing polymyxin E 2 mg, tobramycin 1.8 mg and amphotericin B 10 mg, four times daily during radiotherapy
Study: 12671696
Drug: Placebo lozenges,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges, four times daily during radiotherapy
Study: 12671696
Drug: Active lozenges
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active lozenges (PTA)
Study: 8938220
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cyclophosphamide and methotrexate followed by concomitant 5-fluorouracil and irradiation
Study: 30574609
Drug: Intensive oral
Normalized name: Uricalm Intensive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive oral care programme (IOCP)
Study: 26000622
Drug: Active music
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active music therapy (MT) in addition to speech language therapy (SLT)
Study: 26000622
Drug: Speech language
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech language therapy (SLT) alone
Study: 25151488
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg daily during radiation therapy
Study: 21389934
Drug: Levetiracetam (keppra)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (keppra) as first monotherapy
Study: 21389934
Drug: Levetiracetam (keppra)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (keppra) as second or third monotherapy
Study: 17803835
Drug: Brief eclectic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief eclectic psychotherapy (BEP) in 16 weekly individual sessions
Study: 11890650
Drug: Etanercept (TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (TNF inhibitor)
Study: 11890650
Drug: Infliximab (TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (TNF inhibitor)
Study: 3283292
Drug: Moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (450 mg daily in three divided doses)
Study: 27920262
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise programme filmed on an electronic tablet with automated reminders (n=30)
Study: 19074207
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea catechin beverage (625 mg of catechins with 39 mg caffeine)
Study: 19074207
Drug: Control beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control beverage (39 mg caffeine, no catechins)
Study: 11564123
Drug: Levetiracetam 1,000
Normalized name: Levetiracetam 1,000mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1,000 mg/day
Study: 11564123
Drug: Levetiracetam 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 2,000 mg/day
Study: 9040320
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms of the new hepatitis B vaccine
Study: 9040320
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of the new hepatitis B vaccine
Study: 9040320
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of the new hepatitis B vaccine
Study: 9040320
Drug: 40 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms of the new hepatitis B vaccine
Study: 9040320
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of the new hepatitis B vaccine (single dose)
Study: 2976406
Drug: Acitretin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (30 mg/day initial dose for 4 weeks, mean dose 30.7 mg/day at end of study)
Study: 2976406
Drug: Etretinate (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (initial dose not specified, mean dose 33.4 mg/day at end of study)
Study: 27264224
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg subcutaneous injections
Study: 27264224
Drug: Placebo subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injections
Study: 22948196
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of 2 L of 0.9% saline
Study: 22948196
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 2 L of 0.9% saline
Study: 21191426
Drug: Combination niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination niacin extended-release + simvastatin (NER/S)
Study: 18762754
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 microg kg(‐1) as bolus before induction and 0.2 microg kg(‐1) h(‐1) by infusion
Study: 18762754
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 microg kg(‐1) as bolus before induction and 0.5 microg kg(‐1) h(‐1) by infusion
Study: 15915020
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg intravenous droperidol
Study: 15915020
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intravenous droperidol
Study: 9856967
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg moxonidine
Study: 2744779
Drug: Salbutamol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (8 mg slow release twice daily)
Study: 2744779
Drug: Theophylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300 mg twice daily)
Study: 984352
Drug: Pentobarbitone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbitone (100 mg) given orally
Study: 984352
Drug: Pentobarbitone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbitone (100 mg) given intramuscularly
Study: 984352
Drug: Pentobarbitone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbitone (100 mg) organic preparation (Nembutal)
Study: 984352
Drug: Pentobarbitone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbitone (100 mg) aqueous solution
Study: 984352
Drug: Pentobarbitone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbitone (100 mg) injected by doctors
Study: 984352
Drug: Pentobarbitone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbitone (100 mg) injected by nurses
Study: 25092211
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion of ropivacaine (2 mL/hour of 0.375% ropivacaine after initial 10 mL of 0.75% ropivacaine)
Study: 25092211
Drug: Intermittent epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent epidural ropivacaine (10 mL of 0.75% ropivacaine followed by 10 mL of 0.2% ropivacaine every 6 hours)
Study: 22075651
Drug: Psychodynamic interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic interpersonal therapy (PIT), 12 weekly sessions
Study: 22075651
Drug: Psychodynamic interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic interpersonal therapy (PIT)
Study: 20977840
Drug: Ultra-micronized BYHWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-micronized BYHWD (5 g, twice a day) for 12 weeks
Study: 20977840
Drug: Traditional BYHWD
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional BYHWD (15 g, twice a day) for 12 weeks
Study: 8466735
Drug: Isradipine SRO
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine SRO at 2.5 mg/day (increased to 5 mg/day if DBP remained above 90 mm Hg after 4 weeks)
Study: 8466735
Drug: Enalapril at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril at 10 mg/day (increased to 20 mg/day if DBP remained above 90 mm Hg after 4 weeks)
Study: 30111378
Drug: Immediate prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate prophylactic application of incisional Negative-pressure Wound Therapy (iNPWT) following ILND
Study: 25444821
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal conjugate vaccine (PCV-9)
Study: 7830214
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment condition
Study: 25523633
Drug: Anagliptin (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagliptin (100mg twice daily)
Study: 25523633
Drug: Sitagliptin (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100mg once daily)
Study: 19573436
Drug: High amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High amino acid group (HP): 2.4 g/(kg.d) of amino acid IV within 24 hours after birth
Study: 16159869
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) at 10 microg/kg body weight for 6 days
Study: 11579299
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with ATG
Study: 11579299
Drug: Immediate tacrolimus-based
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate tacrolimus-based triple therapy
Study: 9585718
Drug: Fluoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (up to 60 mg/day for 7 weeks)
Study: 9585718
Drug: Nortriptyline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (3 weeks treatment)
Study: 8142644
Drug: Hu‐M195 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu‐M195 at 0.5, 1.0, 3.0, and 10.0 mg/m2
Study: 8142644
Drug: Hu‐M195 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu‐M195 at 3 mg/m2
Study: 3344597
Drug: Butorphanol 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 4 mg (i.m.)
Study: 3344597
Drug: Butorphanol 2
Normalized name: butorphanol 2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 2 mg (i.m.)
Study: 3344597
Drug: Meperidine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 80 mg (i.m.)
Study: 3344597
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Butorphanol 4 mg, Butorphanol 2 mg, Meperidine 80 mg)
Study: 9756188
Drug: Continued theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued theophylline treatment (400 mg/day) for 6 weeks
Study: 3407871
Drug: Suxamethonium 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 50 mg
Study: 3407871
Drug: Suxamethonium 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 15 mg
Study: 3407871
Drug: Suxamethonium 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 25 mg
Study: 3407871
Drug: Suxamethonium 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 15 mg, 25 mg, 50 mg
Study: 28341107
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of morphine 0.1 mg kg–1 with levobupivacaine 0.5% (1 mg kg–1; group LevoBM)
Study: 28341107
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of morphine 0.1 mg kg–1 with bupivacaine 0.5% (1 mg kg–1; group BM)
Study: 25952661
Drug: BAY 81-8973
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 81-8973 (50 IU kg(-1) dose)
Study: 25952661
Drug: BAY 81-8973
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 81-8973 (single and multiple dosing)
Study: 15282655
Drug: Bivalirudin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin with provisional use of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor
Study: 15282655
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin (UFH) plus planned GP IIb/IIIa inhibitor
Study: 15282655
Drug: Bivalirudin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin with provisional use of GP IIb/IIIa inhibitor
Study: 1490794
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (S)
Study: 26392328
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 150 mg with omeprazole
Study: 26392328
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 150 mg with rabeprazole
Study: 21948118
Drug: Smartseal sealer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartseal sealer and a 0.06 taper Smartpoint calibrated to apical tip size 30
Study: 17469884
Drug: Paroxetine (AD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (AD therapy)
Study: 15669706
Drug: Three narrow‐diameter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three narrow‐diameter roughened‐surface implants placed in edentulous maxillas using a one‐stage surgical procedure.
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 500 mg/day fasting
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 500 mg/day with food
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 750 mg/day fasting
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 750 mg/day with food
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 1000 mg/day fasting
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 1000 mg/day with food
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 1500 mg/day with food
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 750 mg twice/day with food
Study: 10610011
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension with TMP-SMX